E-mail: info@tlph.com.la
Chinese
Nizela (Niraparib)
On October 21, 2021, the Food and Drug Department (FDD) of the Lao Ministry of Health officially approved Niraparib tablets manufactured by TLPH under the trade name Nizela for sale. This is the fifth first-line cancer drug approved by TLPH in 2021.
Instruction manual download
Products

Nizela (Niraparib)nila 800.jpg

Nirapali is a PARP inhibitor. PARP inhibitors are targeted therapies that kill cancer cells by inhibiting PARP-mediated DNA damage repair response (DDR). Using the principle of "synthetic lethality", they can kill cancer cells while leaving healthy cells unaffected.

Other Products
Contact Us
Address: Rd.13 South, 31 km Ban Naphasuk, SaithanyDistrict, Vientiane, Lao PDR
E-mail: info@tlph.com.la
WeChat: TLPH01 Whatsapp:+856 20 76 814 389
Website: https: //tlph.com.la
Copyright © 2017 TLPH. All rights reserved. Technical Support:web100
Copyright © 2017 TLPH. All rights reserved.
Technical Support:web100